WELL Health Technologies Corp (TSE:WELL)
TSX:WELL
Want to see TSE:WELL full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.04Last Year’s EPS
0.1Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and financial picture driven by robust revenue growth (+25% YoY), meaningful margin expansion (adjusted EBITDA +56%; adjusted gross margin +440 bps), accelerating Canadian clinics scale and productivity gains. Strategic initiatives (WIP, WELL Research, CyberWell, Wellstar spinout) and an enlarged credit facility support growth and value unlocking. Near-term headwinds include elevated capex (+88% YoY), a large decline in adjusted free cash flow, Circle Medical compliance and deferred revenue timing, and ongoing strategic reviews of U.S. assets. Management characterized the investment-driven pressures as temporary and reaffirmed FY2026 guidance, while signalling margin expansion from planned cost optimization and AI deployments in H2. Overall, the positive operating momentum, strong KPIs and validated strategy outweigh the temporary financial and execution risks described.Company Guidance
Strong Top-Line Growth
Q1 revenue of $368.3M, up 25% year-over-year (Q1 2025 $294M to Q1 2026 $368.3M). Company reaffirmed FY2026 revenue guidance of $1.55B–$1.65B (reported growth 11%–18%; normalized growth 16%–22% excluding Circle Medical deferrals).
Margin and Profitability Expansion
Adjusted EBITDA of $43.1M in Q1, up 56% year-over-year. Adjusted net income of $15.5M, roughly doubled versus prior year. Adjusted gross profit $163.2M, up 39% YoY, with adjusted gross margin increasing by 440 basis points to 44.3%.
Canadian Clinics—High Growth and Improving Margins
Canadian clinics revenue $130.3M in Q1 and on track to materially exceed $0.5B in 2026. Canadian clinics adjusted EBITDA $17.0M, up 28% YoY. Four-year revenue CAGR ~47% and adjusted EBITDA CAGR ~44%. Primary Care segment adjusted EBITDA margin improved to ~8% (up ~200 bps from 6.2% in Q1 2025).
Material Operational Scale and Productivity Improvements
System-wide patient visits 1.9M in Q1, up 17% YoY; Canadian patient visits ~1.3M (reported growth 31%–33% YoY). Billable providers in Canada 2,204, up 17% YoY. Visits per billable provider increased ~14% YoY to ~576 (from ~510), indicating productivity gains supported by AI and digital tooling.
Wellstar SaaS Momentum
Wellstar revenue $21.8M in Q1, up 27% YoY. Monthly recurring revenue (MRR) $6.4M, up 38% YoY. Wellstar adjusted EBITDA $4.9M, up 14% YoY (excl. $259k spinout-related costs adjusted EBITDA would be $5.2M, +20%).
Healwell Rapid Scale
Healwell revenue $33.2M in Q1, up 316% YoY, with positive adjusted EBITDA of $0.7M compared with a loss of $2.3M in Q1 2025, demonstrating significant margin recovery and customer traction (customers across 11 countries including NHS).
Product and AI-enabled Operational Wins
WELL transcribed and mobilized data for 195,000 fax images using AI in Q1; physicians reportedly save up to 10 hours/week using AI transcription. HealWELL screened >59,000 patient records for disease in Q1. Wellstar billing solutions surpassed $1B in annualized physician pay run rate. NPS ~80 in 2025.
Strategic Platforms and Initiatives Launched
Launched WELL Health Intelligence Platform (WIP) to unify data/AI and accelerate AI deployment and cost optimization; launched WELL Research to consolidate clinical research assets and pivot BPSI toward higher-margin Phase I trials with a target of profitability by end of 2026; consolidated cybersecurity assets into CyberWell with AI-enabled Score Fusion platform and plan to bring in third-party capital partners.
Balance Sheet and Liquidity Enhancements
Cash & equivalents $134M. Expanded and extended senior secured credit facility to CAD 400M with a $100M accordion and maturities extended to Jan 2030, doubling prior capacity and supporting M&A pipeline. Continued NCIB buybacks (177,600 shares repurchased in Q1).
Large M&A Pipeline and Clear Capital Allocation
Pipeline includes >$440M in annual revenue targets across >50 targets and 125+ clinics (WELL Canada: ~$265M revenue under LOI/advanced stage). Management reiterated focused capital allocation toward Canadian clinics and strategic alternatives for non-core assets (Wellstar spinout, U.S. asset review, CyberWell partners).
WELL Health Technologies Corp (TSE:WELL) Earnings, Revenues Date & History
TSE:WELL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:WELL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | C$4.37 | C$4.15 | -5.03% |
Mar 19, 2026 | C$4.21 | C$4.19 | -0.48% |
Nov 06, 2025 | C$4.90 | C$4.50 | -8.16% |
Aug 14, 2025 | C$5.02 | C$4.70 | -6.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does WELL Health Technologies Corp (TSE:WELL) report earnings?
WELL Health Technologies Corp (TSE:WELL) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is WELL Health Technologies Corp (TSE:WELL) earnings time?
WELL Health Technologies Corp (TSE:WELL) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:WELL EPS forecast?
TSE:WELL EPS forecast for the fiscal quarter 2026 (Q2) is 0.04.